Metastatic colon cancer is colon cancer that has spread from its original location to distant organs or tissues in the body. It is classified as stage IV, and the five-year relative survival rate is about 46.6%, according to the most recent data from the National Cancer Institute’s SEER program. While that number is significantly lower than earlier-stage colon cancer, it reflects major improvements in treatment over the past two decades, and many people live years beyond their diagnosis.
How Colon Cancer Spreads
Cancer cells leave the original tumor in the colon through two main routes: the lymphatic system and the bloodstream. Lymphatic vessels have thin, fragile walls made of a single layer of cells with no sturdy outer lining, which makes them relatively easy for cancer cells to penetrate. Once inside, the cells travel through lymph fluid to nearby lymph nodes, where they can take hold, multiply, and eventually move onward to more distant parts of the body.
The other path is through blood vessels. When a tumor grows large enough, it can invade small blood vessels in the colon wall, releasing cells into the bloodstream. These circulating cells can lodge in distant organs and, if conditions are favorable, establish new tumors. The liver is the most common destination because it receives blood directly from the intestines through the portal vein. The lungs are the second most common site, followed by the lining of the abdominal cavity (the peritoneum). Less frequently, colon cancer spreads to bones, the brain, or distant lymph nodes.
Stage IV Substages
Not all metastatic colon cancer is the same. Stage IV is broken into three substages that reflect how widely the cancer has spread:
- Stage IVA: Cancer has reached one distant site or organ, such as the liver alone.
- Stage IVB: Cancer has spread to two or more distant sites or organs.
- Stage IVC: Cancer has spread to the peritoneum, the membrane lining the abdominal cavity, with or without involvement of other organs.
These distinctions matter because they influence which treatments are possible. Someone with a single liver metastasis, for example, may be a candidate for surgery to remove it, while someone with widespread peritoneal involvement typically is not.
Symptoms by Location
The symptoms of metastatic colon cancer depend heavily on where the cancer has traveled. Many people still have symptoms from the original colon tumor, like changes in bowel habits, blood in the stool, or cramping. But the metastases often cause their own distinct set of problems.
When cancer spreads to the liver, it can cause pain in the upper right side of the abdomen, loss of appetite, unintentional weight loss, and a swollen belly from fluid buildup (called ascites). Some people develop jaundice, a yellowing of the skin and the whites of the eyes, along with itchy skin. These symptoms appear because the liver can no longer process waste and fluids normally.
Lung metastases tend to cause a persistent cough, shortness of breath, or coughing up blood. When cancer reaches distant lymph nodes, you may notice swollen nodes above the collarbone or in the groin that weren’t there before. Some people with metastatic disease also experience fatigue and general weakness that goes beyond what their original diagnosis caused.
Genetic Testing Before Treatment
Before any treatment plan is set, your tumor will be tested for several specific genetic markers. This step is considered essential in national guidelines because the results directly determine which therapies will or won’t work for you.
The most important tests look for mutations in genes called KRAS, NRAS, and BRAF. Roughly 40 to 50 percent of metastatic colorectal cancers carry a mutation in one of the RAS genes. People with these mutations do not benefit from a class of targeted drugs that block a growth signal called EGFR, so testing prevents them from receiving an ineffective treatment. BRAF mutations, found in about 9% of cases, also predict a poor response to those same drugs but open the door to a different targeted combination therapy.
Your tumor will also be checked for something called microsatellite instability (MSI) or mismatch repair deficiency (dMMR). Tumors with high microsatellite instability have a specific vulnerability: their DNA repair system is broken, which actually makes them more visible to the immune system. These tumors often respond well to immunotherapy drugs that release the brakes on the body’s immune response. Only a subset of metastatic colon cancers are MSI-high, but for those patients, immunotherapy can produce durable responses that other treatments cannot.
Chemotherapy
Chemotherapy remains the backbone of treatment for most metastatic colon cancer. The three most active drugs are 5-fluorouracil (commonly called 5-FU), oxaliplatin, and irinotecan. These are almost always given in combinations rather than alone, and the two standard regimens have shorthand names: FOLFOX (5-FU plus oxaliplatin) and FOLFIRI (5-FU plus irinotecan).
Survival improves when a person is exposed to all three drugs over the course of treatment. Oncologists often start with one combination and switch to the other if the cancer progresses, or sometimes alternate between the two. Each regimen has a different side effect profile. Oxaliplatin is known for causing numbness and tingling in the hands and feet, especially in cold temperatures. Irinotecan is more likely to cause digestive side effects. Your oncologist will factor in your overall health, the genetic profile of your tumor, and your tolerance when choosing the sequence.
Targeted Therapy and Immunotherapy
Targeted drugs are frequently added to chemotherapy to improve results. Bevacizumab works by blocking a protein called VEGF that tumors use to grow new blood vessels and feed themselves. It is approved for metastatic colorectal cancer regardless of genetic subtype and is one of the most commonly used additions to chemotherapy.
For people whose tumors have no RAS or BRAF mutations (called “wild-type”), drugs like cetuximab and panitumumab are options. These block the EGFR growth signal on the surface of cancer cells. Because RAS and BRAF mutations make the growth signal fire from inside the cell, bypassing the surface receptor entirely, these drugs only help patients without those mutations.
For the roughly 3 to 5 percent of metastatic cases that are MSI-high, immunotherapy can be remarkably effective. Pembrolizumab was approved for MSI-high solid tumors and is now used as a first-line option in some of these patients. The response can be long-lasting, and some patients see their tumors shrink substantially or stabilize for extended periods.
Surgery for Metastatic Disease
Surgery is not off the table just because colon cancer has spread. When metastases are limited to the liver, and sometimes the lungs, removing them surgically can be curative for a select group of patients. The key requirements are that surgeons can remove all visible disease with clear margins, that enough healthy liver tissue remains to function afterward, and that the blood supply and drainage of the remaining liver are preserved.
Candidates for liver surgery generally need to be in reasonable overall health. Other local treatments like thermal ablation (using heat to destroy small tumors) and stereotactic radiation can treat liver metastases that aren’t ideal for surgery due to their location or the patient’s fitness level. Sometimes chemotherapy is given first to shrink metastases enough to make surgery feasible, an approach called conversion therapy.
For people with peritoneal spread, surgical options are more limited. Specialized centers may offer a procedure that combines removal of the peritoneal lining with heated chemotherapy delivered directly into the abdomen, but this is a major operation reserved for carefully selected patients.
What the Survival Numbers Mean
The five-year relative survival rate of 46.6% for distant-stage colorectal cancer, drawn from cases diagnosed between 2015 and 2021, is a population-wide average. It includes people of all ages and health levels, with every tumor subtype and treatment approach. Your individual outlook depends on factors like the number and location of metastases, the genetic profile of your tumor, how well you respond to initial treatment, and whether surgery on metastases is possible.
Younger patients tend to fare better. The data show survival varies meaningfully by age group, with people diagnosed under 50 generally having higher survival rates than those diagnosed at 65 or older. Patients whose tumors are MSI-high or who have resectable liver-only disease often do considerably better than the overall average suggests. These numbers also continue to improve as newer therapies enter standard practice, meaning the statistics from even a few years ago may underestimate what current treatments can achieve.